Tirzepatide Psoriasis Data Don’t Make It a Treatment

The new tirzepatide psoriasis data are encouraging, but they do not make tirzepatide a psoriasis treatment. In two Lilly-funded trials, adults with psoriasis or psoriatic arthritis and obesity or qualifying overweight received Taltz alone or Taltz plus Zepbound. The combination groups more often reached the studies’ skin-or-joint target together with at least 10% weight loss.

That is a useful result for a very specific patient. It does not show that tirzepatide works by itself on psoriasis, that every GLP-1 will do the same thing, or that a compounded formulation will reproduce the results.

What the new tirzepatide psoriasis data found

As of September 9, 2026, the day this article was written, Lilly’s August 31 release is the newest report from TOGETHER-PsO and TOGETHER-PsA. It gives 52-week numbers, but calls those analyses exploratory. Detailed one-year results have not yet appeared in a peer-reviewed paper.

Both phase 3b trials were randomized, meaning chance assigned participants to Taltz alone or Taltz with Zepbound. They were open-label, so participants and study sites knew which treatment they received, although the people scoring skin and joints were kept unaware. TOGETHER-PsO enrolled 274 adults with moderate-to-severe plaque psoriasis. TOGETHER-PsA enrolled 271 adults with active psoriatic arthritis. Everyone also had obesity, or overweight plus another weight-related condition.

Taltz (ixekizumab) is an antibody medicine that blocks IL-17A, an immune signal involved in inflammation. Zepbound contains tirzepatide, which acts at GIP and GLP-1 receptors—gut-hormone signals involved in appetite and blood sugar.

Complete clearance here means PASI 100, or a 100% improvement on the trial’s psoriasis score. ACR50 means at least 50% improvement on a standard arthritis response measure. The separate skin and joint rows matter because the main outcomes counted disease control and weight loss together.

Why weight and psoriatic disease meet in the same study

Psoriasis does not stop at the skin, and psoriatic arthritis does not stop at the joints. Both involve immune activity throughout the body. Fat tissue is active tissue too; at higher amounts, it can release signals that keep low-level inflammation simmering. That helps explain why obesity and psoriatic disease often travel together without proving that one simple pathway causes the other.

There is also a practical treatment issue. A 2024 meta-analysis of 40 studies and 21,438 people found that higher body mass index, or BMI, was associated with a lower chance of a strong response to psoriasis biologics. BMI is a rough weight-for-height measure. The authors cautioned that the effect could differ among medicines.

This is why the TOGETHER trials are interesting: they treated the immune disease with Taltz and the weight condition with Zepbound instead of pretending the two problems never touch.

What the peer-reviewed reports add

The one-year release builds on two 36-week papers. In the TOGETHER-PsO report in JAMA Dermatology, 40.6% of the combination group had complete skin clearance, compared with 29.0% on Taltz alone. The paper also notes an important limitation: there was no tirzepatide-only group. It cannot separate a direct skin effect from weight-related or combined effects.

In the TOGETHER-PsA report in Arthritis & Rheumatology, 33.5% of the combination group reached ACR50 at week 36, compared with 20.4% on Taltz alone. The groups began separating by week 4, before clinically meaningful weight loss, but the authors say more research is needed before calling that a direct anti-inflammatory effect of tirzepatide.

Both studies were funded by Lilly, which makes Taltz and Zepbound. Both were conducted in the United States and excluded people at normal BMI. Those facts do not erase the findings. They define how far the findings can travel.

What this study did not show

It did not test tirzepatide as a replacement for Taltz. It did not compare Zepbound with other psoriasis biologics. It did not study people with psoriasis at normal BMI, and it did not test compounded tirzepatide.

It also does not change the labeled job of either drug. The 2026 FDA label for Zepbound lists long-term weight reduction and obstructive sleep apnea in adults with obesity; psoriasis is not listed. The Taltz label covers plaque psoriasis and active psoriatic arthritis.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The results above came from branded Zepbound used with branded Taltz, not from Promise’s compounded formulation. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor. Compounded tirzepatide explains that separate pathway.

What this means for someone who has psoriasis

For a person already prescribed tirzepatide for weight management, psoriasis belongs on the medication list shared with both clinicians. The dermatologist should know about tirzepatide, and the tirzepatide prescriber should know about Taltz or any other immune treatment. That gives them a chance to watch the skin, joints, stomach symptoms, and injection reactions as one picture.

This news is not a reason to stop, switch, or add a biologic without the dermatologist managing it. It is also not a reason to seek tirzepatide only for a rash or new joint pain. New or worsening symptoms need a diagnosis; psoriasis and psoriatic arthritis can resemble other conditions.

The combination’s adverse events were generally the familiar ones for each medicine. At 52 weeks, Lilly listed nausea, diarrhea, constipation, injection-site reactions, vomiting, dizziness, and headache among events reported in at least 5% of combination participants. The broader tirzepatide side-effects guide covers when a symptom needs a prompt call.

At Promise, a licensed provider reviews every tirzepatide request and may prescribe only when it fits the person’s medical history; not everyone qualifies.